NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates

Stock Information for Inpixon

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inpixon

NervGen Files Management Information Circular and Announces Board of Directors Transition
NervGen Engages Russo Partners LLC to Provide Public Relations Services
NervGen Completes $23 Million Bought Deal Financing
Canadian Investment Regulatory Organization Trade Resumption - NGEN
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING
Canadian Investment Regulatory Organization Trading Halt - NGEN
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
NervGen Pharma Grants Stock Options

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.